Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.
This study has been completed.
Study NCT00737789 Information provided by Ferring Pharmaceuticals
First Received on August 19, 2008. Last Updated on February 13, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ulcerative Colitis
Additional conditions recognized in this trial
Colitis
Colitis, Ulcerative
Ulcer
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Pathologic Processes
Interventions listed in this trial
Mesalazine slow-release granules
Mesalazine liquid enema
Additional drug interventions recognized in this trial
Mesalamine
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Ferring Pharmaceuticals
Back to top of Main Content
